Discovery of novel DNA gyrase inhibitors by high-throughput virtual screening

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 10, 2007, Pages 3688-3698

  Ostrov, David A ^a   Hernández Prada, José A ^a   Corsino, Patrick E ^a   Finton, Kathryn A ^a   Le, Nhan ^a   Rowe, Thomas C ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b College of Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIBIOTIC AGENT; CIPROFLOXACIN; COUMARIN; CYCLOTHIALIDINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GYRASE INHIBITOR; NOVOBIOCIN; NSC 102938; NSC 103003; NSC 130847; NSC 174069; NSC 20091; NSC 20115; NSC 20116; NSC 56902; NSC 56904; NSC 56906; NSC 72730; NSC 72739; NSC 7706; NSC 7761; NSC 7784; NSC 7791; NSC 7861; NSC 7925; NSC 7928; NSC 7936; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RO 09 1437 000; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BINDING SITE; DNA SUPERCOILING; DRUG PROTEIN BINDING; ENZYME INHIBITION; ENZYME SUBUNIT; ESCHERICHIA COLI; HIGH THROUGHPUT SCREENING; NONHUMAN; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATASES; COMPUTER SIMULATION; CRYSTALLIZATION; DATABASES, GENETIC; DNA GYRASE; DNA HELICASES; DNA, SUPERHELICAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, BACTERIAL; ENZYME INHIBITORS; ESCHERICHIA COLI; INDICATORS AND REAGENTS; MOLECULAR CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34948830988     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00392-07     Document Type: Article

References (50)

1. Baxter, C. A., C. W. Murray, B. Waszkowycz, J. Li, R. A. Sykes, R. G. Bone, T. D. Perkins, and W. Wylie. 2000. New approach to molecular docking and its application to virtual screening of chemical databases. J. Chem. Inf. Comput. Sci. 40:254-262.
2. Bellen, S., J. D. Parsons, Y. Wei, K. Hayakawa, L. L. Swenson, P. S. Charifson, J. A. Lippke, R. Aldape, and C. H. Gross. 2004. Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase. Antimicrob. Agents Chemother. 48:1856-1864.
3. Boehm, H. J., M. Boehringer, D. Bur, H. Gmuender, W. Huber, W. Klaus, D. Kostrewa, H. Kuehne, T. Luebbers, N. Meunier-Keller, and F. Mueller. 2000. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J. Med. Chem. 43:2664-2674.
4. Brock, T. D. 1967. Novobiocin, p. 651-760. In D. Gottleib and P. D. Shaw (ed.), Antibiotics, vol. 1. Springer-Verlag, New York, NY.
5. Champoux, J. J. 2001. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 70:369-413.
6. Chenna, R., H. Sugawara, T. Koike, R. Lopez, T. J. Gibson, D. G. Higgins, and J. D. Thompson. 2003. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res. 31:3497-3500.
7. Contreras, A., and A. Maxwell. 1992. gyrB mutations which confer coumarin resistance also affect DNA supercoiling and ATP hydrolysis by Escherichia coli DNA gyrase. Mol. Microbiol. 6:1617-1624.
8. Cullen, M. E., A. W. Wyke, R. Kuroda, and L. M. Fisher. 1989. Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones. Antimicrob. Agents Chemother. 33:886-894.
9. Delano, W. L. 2005. The case for open-source software in drug discovery. Drug Discov. Today 10:213-217.
10. del Castillo, I., J. L. Vizan, M. C. Rodriguez-Sainz, and F. Moreno. 1991. An unusual mechanism for resistance to the antibiotic coumermycin A1. Proc. Natl. Acad. Sci. USA 88:8860-8864.
11. Doman, T. N., S. L. McGovern, B. J. Witherbee, T. P. Kasten, R. Kurumbail, W. C. Stallings, D. T. Connolly, and B. K. Shoichet. 2002. Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J. Med. Chem. 45:2213-2221.
12. Drlica, K., and M. Malik. 2003. Fluoroquinolones: action and resistance. Curr. Top. Med. Chem. 3:249-282.
13. Ewing, T. J., S. Makino, A. G. Skillman, and I. D. Kuntz. 2001. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J. Comput.-Aided Mol. Des. 15:411-428.
14. Friedman, S. M., T. Lu, and K. Drlica. 2001. Mutation in the DNA gyrase A gene of Escherichia coli that expands the quinolone resistance-determining region. Antimicrob. Agents Chemother. 45:2378-2380.
15. Gadelle, D., J. Filee, C. Buhler, and P. Forterre. 2003. Phylogenomics of type II DNA topoisomerases. Bioessays 25:232-242.
16. Gmuender, H., K. Kuratli, K. Di Padova, C. P. Gray, W. Keck, and S. Evers. 2001. Gene expression changes triggered by exposure of Haemophilus influenzae to novobiocin or ciprofloxacin: combined transcription and translation analysis. Genome Res. 11:28-42.
17. Grossman, T. H., D. J. Bartels, S. Mullin, C. H. Gross, J. D. Parsons, Y. Liao, A. L. Grillot, D. Stamos, E. R. Olson, P. S. Charifson, and N. Mani. 2007. Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds. Antimicrob. Agents Chemother. 51:657-666.
18. Heddle, J., and A. Maxwell. 2002. Quinolone-binding pocket of DNA gyrase: role of GyrB. Antimicrob. Agents Chemother. 46:1805-1815.
19. Honma, T., K. Hayashi, T. Aoyama, N. Hashimoto, T. Machida, K. Fukasawa, T. Iwama, C. Ikeura, M. Ikuta, I. Suzuki-Takahashi, Y. Iwasawa, T. Hayama, S. Nishimura, and H. Morishima. 2001. Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J. Med. Chem. 44:4615-4627.
20. Hopkins, K. L., R. H. Davies, and E. J. Threlfall. 2005. Mechanisms of quinolone resistance in Escherichia coli and Salmonella: recent developments. Int. J. Antimicrob. Agents 25:358-373.
21. Irwin, J. J., and B. K. Shoichet. 2005. ZINC - a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 45:177-182.
22. Joubert, F., A. W. Neitz, and A. I. Louw. 2001. Structure-based inhibitor screening: a family of sulfonated dye inhibitors for malaria parasite triosephosphate isomerase. Proteins 45:136-143.
23. Khor, V., C. Yowell, J. B. Dame, and T. C. Rowe. 2005. Expression and characterization of the ATP-binding domain of a malarial Plasmodium vivax gene homologous to the B-subunit of the bacterial topoisomerase DNA gyrase. Mol. Biochem. Parasitol. 140:107-117.
24. Krissinel, E. B., M. D. Winn, C. C. Ballard, A. W. Ashton, P. Patel, E. A. Potterton, S. J. McNicholas, K. D. Cowtan, and P. Emsley. 2004. The new CCP4 Coordinate Library as a toolkit for the design of coordinate-related applications in protein crystallography. Acta Crystallogr. Sect. D 60:2250-2255.
25. Lafitte, D., V. Lamour, P. O. Tsvetkov, A. A. Makarov, M. Klich, P. Deprez, D. Moras, C. Briand, and R. Gilli. 2002. DNA gyrase interaction with coumarin-based inhibitors: the role of the hydroxybenzoate isopentenyl moiety and the 5′-methyl group of the noviose. Biochemistry 41:7217-7223.
26. Lamour, V., L. Hoermann, J. M. Jeltsch, P. Oudet, and D. Moras. 2002. Crystallization of the 43 kDa ATPase domain of Thermus thermophilus gyrase B in complex with novobiocin. Acta Crystallogr. Sect. D 58:1376-1378.
27. Lamour, V., L. Hoermann, J. M. Jeltsch, P. Oudet, and D. Moras. 2002. An open conformation of the Thermus thermophilus gyrase B ATP-binding domain. J. Biol. Chem. 277:18947-18953.
28. Lawrence, J. W., D. C. Claire, V. Weissig, and T. C. Rowe. 1996. Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells. Mol. Pharmacol. 50:1178-1188.
29. Levine, C., H. Hiasa, and K. J. Marians. 1998. DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim. Biophys. Acta 1400:29-43.
30. Lewis, R. J., O. M. Singh, C. V. Smith, T. Skarzynski, A. Maxwell, A. J. Wonacott, and D. B. Wigley. 1996. The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X-ray crystallography. EMBO J. 15:1412-1420.
31. Lindsley, J. E. 2001. Use of a real-time, coupled assay to measure the ATPase activity of DNA topoisomerase II. Methods Mol. Biol 95:57-64.
32. Lubbers, T., P. Angehrn, H. Gmunder, S. Herzig, and J. Kulhanek. 2000. Design, synthesis, and structure-activity relationship studies of ATP analogues as DNA gyrase inhibitors. Bioorg. Med. Chem. Lett. 10:821-826.
33. Mani, N., C. H. Gross, J. D. Parsons, B. Hanzelka, U. Muh, S. Mullin, Y. Liao, A. L. Grillet, D. Stamos, P. S. Charifson, and T. H. Grossman. 2006. In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class. Antimicrob. Agents Chemother. 50:1228-1237.
34. Maxwell, A., and A. J. Howells. 1999. Overexpression and purification of bacterial DNA gyrase. Methods Mol. Biol 94:135-144.
35. Maxwell, A., and D. M. Lawson. 2003. The ATP-binding site of type II topoisomerases as a target for antibacterial drugs. Curr. Top. Med. Chem. 3:283-303.
36. McDonald, I. K., and J. M. Thornton. 1994. Satisfying hydrogen bonding potential in proteins. J. Mol. Biol. 238:777-793.
37. McGovern, S. L., B. T. Helfand, B. Feng, and B. K. Shoichet. 2003. A specific mechanism of nonspecific inhibition. J. Med. Chem. 46:4265-4272.
38. Monga, M., and E. A. Sausville. 2002. Developmental therapeutics program at the NCI: molecular target and drug discovery process. Leukemia 16:520-526.
39. Morais Cabral, J. H., A. P. Jackson, C. V. Smith, N. Shikotra, A. Maxwell, and R. C. Liddington. 1997. Crystal structure of the breakage-reunion domain of DNA gyrase. Nature 388:903-906.
40. Oblak, M., S. G. Grdadolnik, M. Kotnik, R. Jerala, M. Filipic, and T. Solmajer. 2005. In silico fragment-based discovery of indolin-2-one analogues as potent DNA gyrase inhibitors. Bioorg. Med. Chem. Lett. 15:5207-5210.
41. Perola, E., W. P. Walters, and P. S. Charifson. 2004. A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance. Proteins 56:235-249.
42. Peter, B. J., J. Arsuaga, A. M. Breier, A. B. Khodursky, P. O. Brown, and N. R. Cozzarelli. 2004. Genomic transcriptional response to loss of chromosomal supercoiling in Escherichia coli. Genome Biol. 5:R87.
43. Shoichet, B. K., S. L. McGovern, B. Wei, and J. J. Irwin. 2002. Lead discovery using molecular docking. Curr. Opin. Chem. Biol. 6:439-446.
44. Sugino, A., and N. R. Cozzarelli. 1980. The intrinsic ATPase of DNA gyrase. J. Biol. Chem. 255:6299-6306.
45. Wallace, A. C., R. A. Laskowski, and J. M. Thornton. 1995. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 8:127-134.
46. Wang, J. C. 2002. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol. 3:430-440.
47. Wang, J. C., and A. S. Lynch. 1996. Effects of DNA supercoiling on gene expression, p. 127-147. In E. C. C. Lin and A. S. Lynch (ed.), Regulation of gene expression in Escherichia coli. Landes Company, Austin, TX.
48. Wigley, D. B., G. J. Davies, E. J. Dodson, A. Maxwell, and G. Dodson. 1991. Crystal structure of an N-terminal fragment of the DNA gyrase B protein. Nature 351:624-629.
49. Xing, L., E. Hodgkin, Q. Liu, and D. Sedlock. 2004. Evaluation and application of multiple scoring functions for a virtual screening experiment. J. Comput.-Aided Mol. Des. 18:333-344.
50. Yoshida, H., M. Bogaki, M. Nakamura, and S. Nakamura. 1990. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob. Agents Chemother. 34:1271-1272.